Items where authors include "Villa, G."

Export as [feed] Atom [feed] RSS
Jump to: Article
Number of items: 8.

Article

de Boer, A., Villa, G., Bane, O. et al. (25 more authors) (2022) Consensus‐based technical recommendations for clinical translation of renal phase contrast MRI. Journal of Magnetic Resonance Imaging, 55 (2). pp. 323-335. ISSN 1053-1807

Landmesser, U., Lindgren, P., Hagström, E. et al. (7 more authors) (2022) Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden. European Heart Journal - Quality of Care and Clinical Outcomes, 8 (1). pp. 31-38. ISSN 2058-5225

Fonarow, G.C., van Hout, B. orcid.org/0000-0001-9698-6094, Villa, G. et al. (2 more authors) (2019) Updated cost-effectiveness analysis of evolocumab in patients with very high-risk atherosclerotic cardiovascular disease. JAMA Cardiology, 4 (7). pp. 691-695. ISSN 2380-6583

Di Tanna, G.L., Porter, J.K., Lipton, R.B. et al. (5 more authors) (2019) Migraine day frequency in migraine prevention: longitudinal modelling approaches. BMC Medical Research Methodology, 19. 20. ISSN 1471-2288

Lipton, R.B., Brennan, A. orcid.org/0000-0002-1025-312X, Palmer, S. et al. (7 more authors) (2018) Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. Journal of Medical Economics (JME), 21 (7). pp. 666-675. ISSN 1369-6998

Fonarow, G.C., Keech, A.C., Pedersen, T.R. et al. (8 more authors) (2017) Cost-effectiveness of Evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiology, 2 (10). pp. 1069-1078. ISSN 2380-6583

Villa, G., Lothgren, M., Kutikova, L. et al. (7 more authors) (2017) Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain. Clinical Therapeutics, 39 (4). pp. 771-786. ISSN 0149-2918

Gandra, S.R., Villa, G., Fonarow, G.C. et al. (4 more authors) (2016) Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology, 39 (6). pp. 313-320. ISSN 0160-9289

This list was generated on Mon Mar 25 00:14:34 2024 GMT.